Is it time to retire fragile X testing as a first-tier test for developmental delay, intellectual disability, and autism spectrum disorder?
Authors:
Open Access
- 1 December 2017
- journal article
- letter
- Published by Elsevier in Genetics in Medicine
- Vol. 19 (12) , 1380-1381
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Do the data really support ordering fragile X testing as a first-tier test without clinical features?Genetics in Medicine, 2017
- Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disordersScience Translational Medicine, 2014
- Molecular Findings Among Patients Referred for Clinical Whole-Exome SequencingJAMA, 2014
- Comprehensive Evaluation of the Child With Intellectual Disability or Global Developmental DelaysPediatrics, 2014
- Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital AnomaliesThe American Journal of Human Genetics, 2010
- Clinical Genetic Testing for Patients With Autism Spectrum DisordersPediatrics, 2010
- Clinical genetics evaluation in identifying the etiology of autism spectrum disordersGenetics in Medicine, 2008
- Diagnostic yield of chromosome analysis in patients with developmental delay or mental retardation who are otherwise nondysmorphicAmerican Journal of Medical Genetics Part A, 2006
- Screening for fragile X syndrome among Brazilian mentally retarded male patients using PCR from buccal cell DNA.2006
- Fragile X syndrome: Diagnostic and carrier testingGenetics in Medicine, 2005